Abstract
Abstract The aim of T-cell–based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed minimal activity, substantial toxicity, and no biomarkers to identify which patients benefit from treatment, early studies are showing signs that programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) inhibitors are highly active. Preclinical and early data from clinical studies suggest that targeting this pathway can induce durable clinical responses in patients in a variety of tumor types, including lung and colon cancer. Furthermore, correlations with tumor PD-L1 expression may enable selection of patients most likely to benefit from treatment. The emerging data not only offer the hope of better cancer therapy but also provide evidence that changes our understanding of how the host immune system interacts with human cancer. Clin Cancer Res; 18(24); 6580–7. ©2012 AACR.
Keywords
ImmunotherapyMedicineCancerProgrammed cell deathImmune systemLung cancerCancer immunotherapyPD-L1Colorectal cancerCause of deathImmunologyCancer researchBioinformaticsOncologyApoptosisInternal medicineBiologyDisease
Affiliated Institutions
Related Publications
Regulation and Function of the PD-L1 Checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immu...
Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of pati...
Combinations of Bevacizumab With Cancer Immunotherapy
Abstract Cancer immunotherapy (CIT) has transformed cancer treatment. In particular, immunotherapies targeting the programmed death ligand 1 (PD-L1)/programmed death 1 pathway h...
B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer
Over the past few years, there has been a mounting enthusiasm around the potential of immunotherapy in the treatment of non-small cell lung cancer (NSCLC). This interest was cat...
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
Abstract Purpose: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide pat...
Publication Info
- Year
- 2012
- Type
- article
- Volume
- 18
- Issue
- 24
- Pages
- 6580-6587
- Citations
- 635
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
635
OpenAlex
Cite This
Daniel S. Chen,
Bryan Irving,
F. Stephen Hodi
(2012).
Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1.
Clinical Cancer Research
, 18
(24)
, 6580-6587.
https://doi.org/10.1158/1078-0432.ccr-12-1362
Identifiers
- DOI
- 10.1158/1078-0432.ccr-12-1362